Amgen and Allergan plc proposed that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in the United States (U.S.).
MVASI, the first oncology therapeutic biosimilar permitted by the U.S. Food and Drug Administration (FDA), is allowed for the treatment of five types of cancer: together with chemotherapy for metastatic colorectal cancer (mCRC); in combination with chemotherapy for non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; in combination with interferon-alfa for metastatic renal cell carcinoma; and in combination with chemotherapy for persistent, recurrent, or metastatic cervical cancer.
KANJINTI is FDA authorized for all accredited indications of Herceptin: for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
The Wholesale Acquisition Cost (WAC or “checklist value”) of each MVASI and KANJINTI shall be 15% lower than their reference products. MVASI is being made obtainable at a WAC of $677.40 per 100 mg and $2,709.60 per 400 mg single-dose vial, 15% lower than the WAC for Avastin. KANJINTI is being made obtainable at a WAC of $3,697.26 per 420 mg multi-dose vial, 15% under the WAC of Herceptin. At launch, MVASI is priced 12% under the current Avastin Average Selling Price (ASP), and KANJINTI is rated 13% under the present Herceptin ASP. Both products can be available from each wholesaler and specialty distributors.
Actual costs to patients and providers for MVASI and KANJINTI are anticipated to be decrease than WAC as WAC doesn’t replicate discounts or rebates. Out-of-pocket prices to patients will vary relying on insurance status and eligibility for patient help. MVASI and KANJINTI will be available from each wholesaler and specialty distributors.